Petrus Trust Company LTA acquired a new position in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 7,287 shares of the biopharmaceutical company's stock, valued at approximately $227,000.
Several other large investors have also bought and sold shares of RPRX. Two Sigma Advisers LP raised its position in shares of Royalty Pharma by 21.1% in the 4th quarter. Two Sigma Advisers LP now owns 3,673,200 shares of the biopharmaceutical company's stock worth $93,703,000 after acquiring an additional 640,000 shares in the last quarter. Victory Capital Management Inc. raised its position in shares of Royalty Pharma by 270.4% in the 1st quarter. Victory Capital Management Inc. now owns 3,623,134 shares of the biopharmaceutical company's stock worth $112,788,000 after acquiring an additional 2,644,923 shares in the last quarter. Bank of America Corp DE raised its position in shares of Royalty Pharma by 46.7% in the 4th quarter. Bank of America Corp DE now owns 2,985,585 shares of the biopharmaceutical company's stock worth $76,162,000 after acquiring an additional 950,880 shares in the last quarter. Patient Capital Management LLC raised its position in shares of Royalty Pharma by 40.9% in the 4th quarter. Patient Capital Management LLC now owns 2,875,089 shares of the biopharmaceutical company's stock worth $73,344,000 after acquiring an additional 833,894 shares in the last quarter. Finally, AQR Capital Management LLC raised its position in shares of Royalty Pharma by 37.0% in the 1st quarter. AQR Capital Management LLC now owns 2,608,090 shares of the biopharmaceutical company's stock worth $80,381,000 after acquiring an additional 704,414 shares in the last quarter. 54.35% of the stock is owned by institutional investors.
Royalty Pharma Price Performance
Shares of NASDAQ RPRX opened at $36.50 on Wednesday. Royalty Pharma PLC has a twelve month low of $24.05 and a twelve month high of $38.00. The firm has a market cap of $21.29 billion, a P/E ratio of 21.10, a PEG ratio of 2.24 and a beta of 0.58. The company has a 50 day moving average of $36.35 and a 200 day moving average of $34.23. The company has a quick ratio of 1.26, a current ratio of 1.26 and a debt-to-equity ratio of 0.74.
Royalty Pharma (NASDAQ:RPRX - Get Free Report) last issued its earnings results on Wednesday, August 6th. The biopharmaceutical company reported $1.14 EPS for the quarter, beating the consensus estimate of $1.10 by $0.04. Royalty Pharma had a return on equity of 25.54% and a net margin of 44.23%.The business had revenue of $578.67 million for the quarter, compared to the consensus estimate of $750.06 million. As a group, research analysts expect that Royalty Pharma PLC will post 4.49 EPS for the current fiscal year.
Royalty Pharma Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be paid a dividend of $0.22 per share. This represents a $0.88 annualized dividend and a yield of 2.4%. The ex-dividend date is Friday, August 15th. Royalty Pharma's dividend payout ratio (DPR) is currently 50.87%.
Analyst Upgrades and Downgrades
Several research analysts have recently issued reports on RPRX shares. Wall Street Zen raised Royalty Pharma from a "hold" rating to a "buy" rating in a research report on Saturday, August 30th. Morgan Stanley increased their target price on Royalty Pharma from $51.00 to $54.00 and gave the stock an "overweight" rating in a research report on Thursday, July 10th. Finally, Citigroup raised their price objective on Royalty Pharma from $40.00 to $42.00 and gave the company a "buy" rating in a research report on Tuesday, July 22nd. One equities research analyst has rated the stock with a Strong Buy rating and two have issued a Buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $48.00.
Check Out Our Latest Stock Analysis on Royalty Pharma
About Royalty Pharma
(
Free Report)
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.
Featured Articles
Want to see what other hedge funds are holding RPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Royalty Pharma PLC (NASDAQ:RPRX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Royalty Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Royalty Pharma wasn't on the list.
While Royalty Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
